Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | VDR | P11473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4852373 | 0.72 | OPRM1 (0.46) | HTR6ALDH1A1KMT2AVDRMEN1 | |
| SCHEMBL20476017 | 0.68 | CYP2D6 (0.36) | HTR6SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL11253475 | 0.67 | HTR2A (0.47) | HTR6SLC6A2SLC6A3KCNH2ALDH1A1 | |
| SCHEMBL7751891 | 0.66 | OPRM1 (0.41) | HTR6ALDH1A1KMT2AVDRMEN1 | |
| SCHEMBL4829535 | 0.66 | HTR6 (0.36) | HTR6SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4957688 | 0.63 | CHRNB4 (0.56) | HTR6ALDH1A1 | |
| SCHEMBL11253846 | 0.63 | HTR6 (0.36) | HTR6ALDH1A1KMT2AVDRKEAP1 | |
| SCHEMBL22392313 | 0.62 | NPSR1 (0.39) | ALDH1A1VDRNPSR1KEAP1NFE2L2 | |
| SCHEMBL22392314 | 0.62 | ALDH1A1 (0.39) | ALDH1A1KMT2AVDRMEN1 | |
| SCHEMBL8827430 | 0.62 | CYP2D6 (0.38) | HTR6ALDH1A1KMT2AVDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205300-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2007-04-17 | — | — | US | disclosed |
| US-7144882-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1259489-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1619192-A2 | Aryl fused azapolycyclic compounds | Pfizer Products Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-6605610-B1 | Reducing nicotine addiction; treating neurological and psychological disorders | PFIZER INC | 2003-08-12 | — | — | US | disclosed |
| US-20030130260-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2003-07-10 | — | — | US | disclosed |
| EP-1259489-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001062736-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130260-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN3A | HTR6 65/4885SLC6A2 329/4885SLC6A4 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.